Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Immunology
Study findings from Jozef Stefan Institute broaden understanding of cancer immunology
May 21st, 2008
A report, 'Generation of ammodytoxin-anti-cathepsin B immuno-conjugate as a model for delivery of secretory phospholipase A2 into cancer cells,' is newly published data in Toxicon. "Ammodytoxin C (AtxC) is a toxic secreted phospholipase A2 (sPLA2) from the venom of Vipera ammodytes snake. To evaluate its potential to kill cancer cells, the toxin was cross-linked to the monoclonal antibody against cathepsin B which endocytoses upon binding to cathepsin B, an antigen overexpressed on the plasma membrane of cancer cells," researchers in Ljubljana, Slovenia report. "A photo-reactive derivative of AtxC, possessing the same biological activity as the native toxin, was...
Source: Immunotherapy Weekly (2008-05-21)
|
